Alkermes plc. (NASDAQ: ALKS)

Alkermes plc, a prominent player in the biopharmaceutical industry, is publicly traded on the Nasdaq stock exchange under the symbol ALKS and boasts a market capitalization of over $10 billion. The company's primary focus is on neuroscience, and it has established a strong presence in this field with a portfolio of proprietary commercial products and a pipeline of clinical and preclinical candidates in development.

Alkermes' main business activities revolve around the development, manufacture, and marketing of pharmaceutical products for the treatment of various neurological disorders. The company operates in several countries, including the United States and Ireland, and has a global workforce of over 2,100 employees.

The company generates revenue through the sale of its products, including royalties and manufacturing and other revenues from the commercialization of licensed products by third parties. Alkermes' primary products include ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL, and VUMERITY. ARISTADA is an extended-release intramuscular injectable suspension approved for the treatment of schizophrenia, while ARISTADA INITIO is used for the initiation of ARISTADA. LYBALVI is a once-daily, oral atypical antipsychotic drug approved for the treatment of adults with schizophrenia and bipolar I disorder. VIVITROL is a once-monthly, non-narcotic, injectable medication approved for the treatment of alcohol dependence and opioid dependence. VUMERITY is a novel, oral fumarate approved for the treatment of relapsing forms of multiple sclerosis.

Alkermes' position within the industry is strong, with a portfolio of proprietary commercial products and a pipeline of clinical and preclinical candidates in development. The company has a number of collaborative arrangements with third parties, including Janssen and Biogen, which provide access to technological, financial, marketing, manufacturing, and other resources. The company faces intense competition in the development, manufacture, marketing, and commercialization of its products from many and varied sources, including research institutions and biopharmaceutical companies.

Alkermes' proprietary technology platforms include injectable extended-release microsphere technology, LinkeRx technology, and NanoCrystal technology, which enable the development of novel formulations of pharmaceuticals, including extended-release injectable products and solid dosage forms. The company is subject to substantial government regulation in the United States and other countries, including the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe.

The company's marketing and sales efforts are focused on physicians in private practice and in public treatment systems, and it provides customer services and other related programs for its products. Alkermes has established various policies and procedures to ensure the health and safety of its employees and the environment, and it has a strong focus on diversity, equity, and inclusion.

Alkermes has reported significant revenue growth over the past few years, driven by the success of its products and the expansion of its pipeline. The company's products are subject to pricing and reimbursement policies in various countries, including the United States, and they are also subject to various cost-containment measures, including price cuts, mandatory rebates, value-based pricing, and reference pricing.